Cytomegalovirus infection decreases expression of thrombospondin-1 and -2 in cultured human retinal glial cells: effects of antiviral agents.
In fibroblasts, infection with human cytomegalovirus (HCMV) inhibits expression of the extracellular matrix proteins thrombospondin-1 and -2 (TSP-1 and TSP-2). These effects may depend on expression of HCMV immediate-early (IE) genes, which are activated by cellular transcription factor NF-kappaB. The influence of HCMV infection on TSP-1 and TSP-2 expression and the ability of different antiviral drugs to prevent these cellular changes in permissive cultures of human retinal glial cells were observed. Ganciclovir inhibited only HCMV late antigen (LA) expression, whereas antisense oligonucleotide ISIS 2922 and peptide SN50, inhibitors of HCMV IE expression and NF-kappaB activity, respectively, inhibited both IE and LA expression. ISIS 2922 and SN50, but not ganciclovir, prevented down-modulation of TSP-1 and TSP-2. The results showed that HCMV-induced down-modulation of TSP-1 and TSP-2 in retinal glial cells is prevented by inhibition of HCMV IE expression. These findings may be relevant to pathogenesis and treatment of HCMV retinitis.
Cinatl
J
J
Institut für Medizinische Virologie, Zentrum der Hygiene, Klinikum der Johann Wolfgang Goethe-Universität, D-60596 Frankfurt am Main, Germany. cinatl@em.uni-frankfurt.de
Bittoova
M
M
Margraf
S
S
Vogel
J U
JU
Cinatl
J
J
Preiser
W
W
Doerr
H W
HW
D000998:Antiviral Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D017726:Cytomegalovirus Retinitis / Q000378:metabolism*; D015536:Down-Regulation; D004591:Electrophoresis, Polyacrylamide Gel; D005434:Flow Cytometry; D015774:Ganciclovir / Q000494:pharmacology; D006801:Humans; D017874:Immediate-Early Proteins / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D009457:Neuroglia / Q000187:drug effects / Q000378:metabolism*; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D012160:Retina / Q000187:drug effects / Q000378:metabolism*; D019700:Thrombospondin 1 / Q000096:biosynthesis*; D019699:Thrombospondins / Q000096:biosynthesis*; D014779:Virus Replication / Q000187:drug effects; D000099262:Thrombospondin 2
D000998:Antiviral Agents; D015774:Ganciclovir; D017874:Immediate-Early Proteins; D016328:NF-kappa B; D020319:Oligodeoxyribonucleotides, Antisense; D010455:Peptides; D019700:Thrombospondin 1; D019699:Thrombospondins; D000099262:Thrombospondin 2; C118258:SN50 peptide